CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Administration of Lymphodepletion +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01005745
NCT01005745N/ACompleted
CompareCT.gov

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Nov 2, 2009·Updated Dec 19, 2025

In Brief

A clinical study evaluating Surgery, Administration of Lymphodepletion, and 2 other interventions for Metastatic Melanoma. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The overall purpose of this research study is to find a better way to treat melanoma. This will be a single arm exploratory trial to evaluate prospectively the feasibility of, the toxicities of, and the persistence of TIL which can survive in vivo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2, 2009
Enrollment StartOct 20, 2009
Primary CompletionJan 31, 2014
Study CompletionAug 18, 2025
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.7 years ago

Interventions

Surgeryprocedure

Surgery to remove a tumor for growth of TIL

Administration of Lymphodepletiondrug

Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo

Adoptive Cell Transferother

T-cell infusion

High Dose IL-2drug

Beginning approximately 12 - 16 hours after cell infusion.